Effect of dendritic cell immunotherapy on distribution of dendritic cell subsets in non-small cell lung cancer

Yang,Zhongfei; Deng,Fang; Meng,Lingjun

doi:10.3892/etm.2018.6010

Effect of dendritic cell immunotherapy on distribution of dendritic cell subsets in non-small cell lung cancer

Authors:
- Zhongfei Yang
- Fang Deng
- Lingjun Meng
View Affiliations

Affiliations: Department of Pneumology, Dezhou People's Hospital, Dezhou, Shandong 253000, P.R. China, Department of Oncology, Dezhou People's Hospital, Dezhou, Shandong 253000, P.R. China
Published online on: March 30, 2018 https://doi.org/10.3892/etm.2018.6010
Pages: 4856-4860
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The effect of dendritic cell (DC) immunotherapy on non-small cell lung cancer (NSCLC) and its influence on the distribution of DC subsets were studied. Peripheral blood was drawn from 55 patients, and DCs were cultured in vitro and injected into the patients three times. The changes in DC subsets in NSCLC patients before treatment and after three treatments were observed using a flow cytometer, and the difference in DC subsets between patients and healthy controls was compared. DC subsets in lung cancer tissues, para-carcinoma tissues and normal tissues were analyzed by indirect immunofluorescence and laser scanning confocal microscope (LSCM). The BDCA-1+ DC1 and BDCA-3+ DC2 in lung cancer tissues were significantly increased compared with those in para-carcinoma tissues and normal tissues (P<0.05). The number of DC1 and DC2 in para-carcinoma tissues were increased compared with those in normal tissues (P<0.05). The ratio of DC1 in peripheral blood in the normal control group was obviously higher than that in NSCLC patients (P<0.01). There were significant differences in DC1 and DC1/DC2 ratio in NSCLC patients with different tumor staging, and there were also obvious differences in patients with a different Karnofsky performance status (KPS) score. Moreover, compared with those before treatment, DC1 and DC1/DC2 ratio were significantly increased after three treatments, and there was a significant difference in the comparison of DC1/DC2 ratio between the NSCLC patients with survival time greater than and less than one year. The immune function of NSCLC patients was improved after DC immunotherapy. The survival time of NSCLC patients was closely associated with the DC1/DC2 ratio in peripheral blood. The detection of DC subsets in peripheral blood can help clinicians understand the immune function of NSCLC patients and provide a basis for the clinical judgment of prognosis of NSCLC patients.

View Figures

View References

1	Teramoto K, Ozaki Y, Hanaoka J, Sawai S, Tezuka N, Fujino S, Daigo Y and Kontani K: Predictive biomarkers and effectiveness of MUC1-targeted dendritic-cell-based vaccine in patients with refractory non-small cell lung cancer. Ther Adv Med Oncol. 9:147–157. 2017. View Article : Google Scholar : PubMed/NCBI
2	Zhang L, Yang X, Sun Z, Li J, Zhu H, Li J and Pang Y: Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer. Oncol Lett. 11:2605–2610. 2016. View Article : Google Scholar : PubMed/NCBI
3	Li R, Fang F, Jiang M, Wang C, Ma J, Kang W, Zhang Q, Miao Y, Wang D, Guo Y, et al: STAT3 and NF-κB are simultaneously suppressed in dendritic cells in lung cancer. Sci Rep. 7:453952017. View Article : Google Scholar : PubMed/NCBI
4	Mendoza L: Dendritic cell vaccines against non-small cell lung cancer - an emerging therapeutic alternative. Klin Onkol. 27:294–298. 2014.PubMed/NCBI
5	Liu X, Li J and Liu Y, Ding J, Tong Z and Liu Y, Zhou Y and Liu Y: Calreticulin acts as an adjuvant to promote dendritic cell maturation and enhances antigen-specific cytotoxic T lymphocyte responses against non-small cell lung cancer cells. Cell Immunol. 300:46–53. 2016. View Article : Google Scholar : PubMed/NCBI
6	Zhou C, Liu D, Li J, Sun H, Zheng X, Wang S, Hong G, Mallampati S, Sun H, Zhou X, et al: Chemotherapy plus dendritic cells co-cultured with cytokine-induced killer cells versus chemotherapy alone to treat advanced non-small-cell lung cancer: A meta-analysis. Oncotarget. 7:86500–86510. 2016. View Article : Google Scholar : PubMed/NCBI
7	Rafei H, El-Bahesh E, Finianos A, Nassereddine S and Tabbara I: Immune-based therapies for non-small cell lung cancer. Anticancer Res. 37:377–387. 2017. View Article : Google Scholar : PubMed/NCBI
8	Shi SB, Tang XY, Tian J, Chang CX, Li P and Qi JL: Efficacy of erlotinib plus dendritic cells and cytokine-induced killer cells in maintenance therapy of advanced non-small cell lung cancer. J Immunother. 37:250–255. 2014. View Article : Google Scholar : PubMed/NCBI
9	Zhao M, Li H, Li L and Zhang Y: Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients. Exp Ther Med. 7:1403–1407. 2014. View Article : Google Scholar : PubMed/NCBI
10	Takahashi H, Okamoto M, Shimodaira S, Tsujitani S, Nagaya M, Ishidao T, Kishimoto J and Yonemitsu Y: DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT): Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers. Eur J Cancer. 49:852–859. 2013. View Article : Google Scholar : PubMed/NCBI
11	Zhong R, Han B and Zhong H: A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients. Tumour Biol. 35:987–994. 2014. View Article : Google Scholar : PubMed/NCBI
12	Aguilar-Cazares D, Meneses-Flores M, Prado-Garcia H, Islas-Vazquez L, Rojo-Leon V, Romero-Garcia S, Rivera-Rosales RM and Lopez-Gonzalez JS: Relationship of dendritic cell density, HMGB1 expression, and tumor-infiltrating lymphocytes in non-small cell lung carcinomas. Appl Immunohistochem Mol Morphol. 22:105–113. 2014. View Article : Google Scholar : PubMed/NCBI
13	Hradilova N, Sadilkova L, Palata O, Mysikova D, Mrazkova H, Lischke R, Spisek R and Adkins I: Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy. PLoS One. 12:e01715392017. View Article : Google Scholar : PubMed/NCBI
14	Zhu XP, Xu YH, Zhou J and Pan XF: A clinical study evaluating dendritic and cytokine-induced killer cells combined with concurrent radiochemotherapy for stage IIIB non-small cell lung cancer. Genet Mol Res. 14:10228–10235. 2015. View Article : Google Scholar : PubMed/NCBI
15	Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, Le Chevalier T, Livartoski A, Barlesi F, Laplanche A, et al: Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology. 5:e10710082015. View Article : Google Scholar : PubMed/NCBI
16	Han RX, Liu X, Pan P, Jia YJ and Yu JC: Effectiveness and safety of chemotherapy combined with dendritic cells co-cultured with cytokine-induced killer cells in the treatment of advanced non-small-cell lung cancer: A systematic review and meta-analysis. PLoS One. 9:e1089582014. View Article : Google Scholar : PubMed/NCBI
17	Yuanying Y, Lizhi N, Feng M, Xiaohua W, Jianying Z, Fei Y, Feng J, Lihua H, Jibing C, Jialiang L, et al: Therapeutic outcomes of combining cryotherapy, chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer. Cryobiology. 67:235–240. 2013. View Article : Google Scholar : PubMed/NCBI
18	Kovarova L, Buchler T, Pour L, Zahradova L, Ocadlikova D, Svobodnik A, Penka M, Vorlicek J and Hajek R: Dendritic cell counts and their subsets during treatment of multiple myeloma. Neoplasma. 54:297–303. 2007.PubMed/NCBI
19	Ma J, Liu H and Wang X: Effect of ginseng polysaccharides and dendritic cells on the balance of Th1/Th2 T helper cells in patients with non-small cell lung cancer. J Tradit Chin Med. 34:641–645. 2014. View Article : Google Scholar : PubMed/NCBI
20	Zhang L, Xu Y, Shen J, He F, Zhang D, Chen Z, Duan Y and Sun J: Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer. Radiat Oncol. 11:602016. View Article : Google Scholar : PubMed/NCBI
21	Zhao P, Bu X, Wei X, Sun W, Xie X, Li C, Guo Q, Zhu D, Wei X and Gao D: Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer. Int Immunopharmacol. 25:450–456. 2015. View Article : Google Scholar : PubMed/NCBI